Combination therapy reduces symptoms and joint erosion in rheumatoid arthritisBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7439.544-c (Published 04 March 2004) Cite this as: BMJ 2004;328:544
- Susan Mayor
The combination of etanercept (a drug that blocks tumour necrosis factor) and methotrexate achieves significantly greater reduction in symptoms and joint erosion than either drug used alone, a trial published in the Lancet last week has found.
The study randomised 686 participants with active, adult onset, rheumatoid arthritis to etanercept (25 mg subcutaneously twice a week) or oral methotrexate (up to 20 mg every week), or a combination of both drugs.
The mean age of the participants was about 53 years, with mean disease duration of 6.3 to 6.8 years (range 6 months to 20 years). All participants …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial